Differential effects of non‐selective and selective phosphodiesterase inhibitors on human eosinophil functions

British Journal of Pharmacology

Volumn 114, Issue 4, 1995, Pages 821-831

  Hatzelmann, Armin ^a   Tenor, Hermann ^b   Schudt, Christian ^a  

^a Department of Biochemistry ^*  (Germany)

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

chemiluminescence; complement C5a; eosinophil cationic protein; eosinophil derived neurotoxin; Human eosinophils; phosphodiesterase inhibitors; phosphodiesterase IV; xanthines

Indexed keywords

COMPLEMENT COMPONENT C5A; CYCLIC AMP; FORMYLMETHIONYLLEUCYLPHENYLALANINE; ISOBUTYLMETHYLXANTHINE; NEUROTOXIN; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PICLAMILAST; PROTEIN; REACTIVE OXYGEN METABOLITE; ROLIPRAM; SALBUTAMOL; THEOPHYLLINE; THROMBOCYTE ACTIVATING FACTOR; TOLAFENTRINE; UNCLASSIFIED DRUG; ZARDAVERINE; ZYMOSAN;

ARTICLE; CELL FREE SYSTEM; CELL FUNCTION; CELL GRANULE; CHEMOLUMINESCENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DRUG POTENCY; ENZYME ACTIVITY; EOSINOPHIL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

1-METHYL-3-ISOBUTYLXANTHINE; ADRENERGIC BETA-ANTAGONISTS; BENZAMIDES; BLOOD PROTEINS; CELL SEPARATION; CHEMILUMINESCENCE; COMPLEMENT 5A; ELECTROMAGNETIC FIELDS; EOSINOPHILS; HUMAN; INFLAMMATION MEDIATORS; NAPHTHYRIDINES; NEUROTOXINS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PYRIDAZINES; PYRIDINES; PYRROLIDINONES; RIBONUCLEASE, PANCREATIC; ROLIPRAM; THEOPHYLLINE;

EID: 0028944033     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1995.tb13278.x     Document Type: Article

References (38)

1. Eosinophil granule proteins in peripheral blood granulocytes
2. Pitfalls in the quantitative estimation of the secretion of granule proteins in eosinophils
3. New aspects of asthma
4. Efficacy and safety of inhaled corticosteroids in asthma
5. An improved assay of cyclic 3′,5′‐nucleotide phosphodiesterase with QAE Sephadex A‐25
6. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors
7. Contribution of eosinophil‐derived mediators in asthma
8. Zardaverine inhibits respiratory burst activity in human eosinophils
9. Inhibition of eosinophil cyclic nucleotide PDE activity and opsonized zymosan‐stimulated respiratory burst by type IV‐selective PDE inhibitors
10. Inhibitory effects of formoterol on platelet‐activating factor induced eosinophil chemotaxis and de‐granulation
11. Could isoenzyme‐selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma
12. Stimulus‐response coupling in eosinophils
13. The eosinophil and bronchial asthma: current understanding
14. The eosinophilic leukocyte: structure and function
15. An improved imnunagnetic procedure for the isolation of highly purified human blood eosinophils
16. Anti‐inflammatory effects of novel selective cyclic nucleotide phosphodiesterase inhibitors
17. Regulation of Ig‐induced eosinophil degranulation by adenosine 3′,5′‐cyclic monophosphate
18. Effect of phosphodiesterase IV inhibitor (WAY‐PDA‐641) on PAF‐induced superoxide generation from human eosinophils
19. Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase‐deficient Saccharomyces cerevisiae
20. Current issues in the use of theophylline
21. 4
22. i
23. Enhancement of antigen‐induced bronchoconstriction after intravascular complement activation with cobra venom factor
24. Role of the complement system in antigen‐induced bronchoconstriction and changes in blood pressure in the guinea‐pig
25. Activated eosinophils evoke chloride secretion in model intestinal epithelia primarily via regulated release of 5′‐AMP
26. i
27. Zar‐daverine as a selective inhibitor of phosphodiesterase isozymes
28. Influence of the PDE III/IV inhibitor B9004–070 in contraction and PDE activities in airway and vascular smooth muscle
29. Differential inhibition of phosphodiesterase inhibitors of I1–5 and PAF induced chemotactic responses of normal and atopic human eosinophils
30. 3‐Isobutyl‐1‐methylxanthine inhibits sustained calcium current independently of cyclic AMP in neuronal and endocrine cells
31. Characterization of guinea‐pig eosinophil phosphodiesterase activity
32. Effects of solubilization and vanadate/glutathione complex on inhibitor potencies against eosinophil cyclic AMP‐specific phosphodiesterase
33. Anti‐inflammatory effects of low‐dose oral theophylline in atopic asthma
34. Effects of phosphodiesterase IV inhibitor (WAY‐PDA‐641) on human eosinophil and neutrophil migration in vitro
35. Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme
36. Isobutylmethylxanthine and other classical cyclic nucleotide phosphodiesterase inhibitors effect cAMP‐dependent protein kinase activity
37. Adenosine receptor‐blocking xanthines as inhibitors of phosphodiesterase isozymes
38. 2‐adrenergic receptors on eosinophils